Key result
Vericiguat reaches target dose in ~91% of patients with worsening heart failure without new safety signals.
Why the study?
Patients with HFrEF in India experience worsening heart failure events despite optimal therapy, and vericiguat's real-world effectiveness and safety require evaluation.
Observational (n=205)
Yes
In a real-world Indian cohort of patients with worsening HFrEF, vericiguat was successfully titrated to the target dose of 10 mg in 91.1% of patients with no new safety signals.
Answers are grounded in this paper and cite their sources.
Supports vericiguat titration to target in Indian worsening HFrEF; leaves open long-term effectiveness versus global cohorts.
INTRODUCTION: Patients with heart failure with reduced ejection fraction (HFrEF) experience higher rates of in-hospital and all-cause mortality. On the basis of the VERINA trial, vericiguat is indicated for patients who have had a worsening heart failure (WHF) event despite optimal heart failure (HF) therapy, or for those with tolerability concerns. METHODS: This multicenter, prospective, single-arm, non-randomized, real-world, descriptive study assessed the efficacy and safety of vericiguat in Indian patients aged ≥18 years with chronic HFrEF who were vericiguat-naïve and started treatment as per the local label. This analysis is based on interim data and the final results may differ. The main endpoint was a composite of cardiovascular (CV) death or first HF hospitalization. Secondary endpoints included each component of the primary outcome, all-cause death, and safety. Dose-titration parameters, including time to reach and duration at various dose levels, were also assessed. RESULTS: A total of 205 patients were enrolled (58.0 ± 13.27 years; 73.7% male; 34.1% aged ≥ 65 years, baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) 2490.1 pg/mL). Left ventricular ejection fraction (LVEF) < 30% was observed in 48.8% patients, 24.9% were in New York Heart Association (NYHA) class III. WHF events included recent HF hospitalization within < 7 days (10.7%) or 7 days-3 months (30.2%). Common background therapies included β-blockers (84.9%), mineralocorticoids receptor antagonist (MRAs) (80.5%), sodium-glucose cotransporter 2 (SGLT2) inhibitors (75.6%), and angiotensin receptor-neprilysin inhibitor (ARNI) (52.7%), with 66.3% receiving triple HF therapy. Vericiguat target dose (10 mg) was achieved by 91.1% of patients. CONCLUSION: This study enrolled high-risk patients with recent decompensation event consistent with the VICTORIA trial. The usage of standard of care (SoC) was as per current clinical practice in HF; VERINA enrolled 52.7% on ARNI compared to 14.5% in VICTORIA and 75.6% on SGLT2i compared to 2% in VICTORIA. Safety data did not reveal any new safety signals or adverse trends in the interim analysis. TRIAL REGISTRATION: Clinical Trials Registry of India (CTRI/2022/11/047636).
No takes yet. Share an insight, caveat, or question.
Abdulakutty et al. (2025) conducted an observational in Worsening heart failure with reduced ejection fraction (HFrEF) (n=205). Vericiguat was evaluated on Composite of cardiovascular (CV) death or first HF hospitalization. In this interim analysis of a real-world cohort of 205 Indian patients with worsening heart failure, 91.1% achieved the vericiguat target dose of with no new safety signals observed.
Synapse has enriched 10 related papers. Consider them for comparative context: